LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences, a clinical stage biopharmaceutical company, today announced that ASN002, its oral once daily dual JAK/SYK inhibitor, has achieved clinical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results